As of 2024-07-27, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -2.29. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 273.70 mil USD. INO's TTM EBITDA according to its financial statements is -119.46 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 21.5x | 16.6x |
| Forward P/E multiples | 17.8x - 24.1x | 21.4x |
| Fair Price | (81.31) - (98.37) | (86.85) |
| Upside | -818.3% - -969.0% | -867.2% |
| Date | EV/EBITDA |
| 2024-07-26 | -2.29 |
| 2024-07-25 | -2.21 |
| 2024-07-24 | -2.18 |
| 2024-07-23 | -2.26 |
| 2024-07-22 | -2.13 |
| 2024-07-19 | -2.02 |
| 2024-07-18 | -2.09 |
| 2024-07-17 | -2.24 |
| 2024-07-16 | -2.25 |
| 2024-07-15 | -2.23 |
| 2024-07-12 | -2.29 |
| 2024-07-11 | -2.23 |
| 2024-07-10 | -1.85 |
| 2024-07-09 | -1.82 |
| 2024-07-08 | -1.72 |
| 2024-07-05 | -1.77 |
| 2024-07-03 | -1.64 |
| 2024-07-02 | -1.66 |
| 2024-07-01 | -1.70 |
| 2024-06-28 | -1.59 |
| 2024-06-27 | -1.52 |
| 2024-06-26 | -1.53 |
| 2024-06-25 | -1.50 |
| 2024-06-24 | -1.56 |
| 2024-06-21 | -1.59 |
| 2024-06-20 | -1.59 |
| 2024-06-18 | -1.69 |
| 2024-06-17 | -1.77 |
| 2024-06-14 | -1.81 |
| 2024-06-13 | -1.89 |
| 2024-06-12 | -1.89 |
| 2024-06-11 | -1.94 |
| 2024-06-10 | -1.94 |
| 2024-06-07 | -1.92 |
| 2024-06-06 | -2.01 |
| 2024-06-05 | -2.03 |
| 2024-06-04 | -2.02 |
| 2024-06-03 | -2.04 |
| 2024-05-31 | -2.03 |
| 2024-05-30 | -1.95 |
| 2024-05-29 | -2.01 |
| 2024-05-28 | -2.09 |
| 2024-05-24 | -2.22 |
| 2024-05-23 | -2.21 |
| 2024-05-22 | -2.28 |
| 2024-05-21 | -2.22 |
| 2024-05-20 | -2.25 |
| 2024-05-17 | -2.44 |
| 2024-05-16 | -2.61 |
| 2024-05-15 | -2.67 |